ChiCTR2000040932 版本V1.1 版本创建时间2021/04/04 01:05:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000040932 

最近更新日期:

Date of Last Refreshed on:

2021-04-04 00:59:13 

注册时间:

Date of Registration:

2020-12-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脐带间充质干细胞与MEEK植皮联合救治大面积烧伤的研究

Public title:

Combined Treatment of Umbilical Cord Mesenchymal Stem Cells and MEEK Micrografting on Severe Burn Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脐带间充质干细胞与MEEK植皮联合救治战时大面积烧伤的研究

Scientific title:

Combined Treatment of Umbilical Cord Mesenchymal Stem Cells and MEEK Micrografting on Severe Burn Patients in Wartime

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖荣 

研究负责人:

肖荣 

Applicant:

Xiao Rong 

Study leader:

Xiao Rong 

申请注册联系人电话:

Applicant telephone:

+86 18625316120

研究负责人电话:

Study leader's telephone:

+86 18625316120

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xr131@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

xr131@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省驻马店市风光路南段1号第990医院烧伤科

研究负责人通讯地址:

河南省驻马店市风光路南段1号第990医院烧伤科

Applicant address:

Burn Center, the 990th Hospital of PLA, 1 Fengguang Road South, Yicheng District, Zhumadian, Henan, China

Study leader's address:

Burn Center, the 990th Hospital of PLA, 1 Fengguang Road South, Yicheng District, Zhumadian, Henan, China

申请注册联系人邮政编码:

Applicant postcode:

463000

研究负责人邮政编码:

Study leader's postcode:

463000

申请人所在单位:

中国人民解放军联勤保障部队第九九〇医院

Applicant's institution:

The 990th Hospital of PLA

研究负责人所在单位:

中国人民解放军联勤保障部队第九九〇医院

Affiliation of the Leader:

The 990th Hospital of PLA

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020年第11-1号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军联勤保障部队第九九〇医院伦理学委员会

Name of the ethic committee:

Ethics Committee of the 990th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army

伦理委员会批准日期:

Date of approved by ethic committee:

2020-11-06 00:00:00

伦理委员会联系人:

周树长

Contact Name of the ethic committee:

Zhou Shuchang

伦理委员会联系地址:

河南省驻马店市驿城区风光路南段1号第990医院

Contact Address of the ethic committee:

1 Fengguang Road South, Yicheng District, Zhumadian, Henan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 15938002805

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军联勤保障部队第九九〇医院

Primary sponsor:

The 990th Hospital of PLA

研究实施负责(组长)单位地址:

河南省驻马店市风光路南段1号第990医院

Primary sponsor's address:

1 Fengguang Road South, Yicheng District, Zhumadian, Henan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

驻马店

Country:

China

Province:

Henan

City:

Zhumadian

单位(医院):

联勤保障部队第九九〇医院

具体地址:

驻马店市风光路南段1号

Institution
hospital:

The 990th Hospital of PLA

Address:

1 Fengguang Road South, Yicheng District

经费或物资来源:

军队医学科技青年培育计划孵化项目(20QNPY074)

Source(s) of funding:

Incubation Project of Military Medical Science and Technology for Youth Training (20QNPY074)

Target disease:

Burns

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究通过联合脐带间充质干细胞(UCMSCs)与MEEK植皮这两种治疗烧伤创面的新型先进技术,形成优势互补,利用MEEK植皮术最大限度节省皮源,利用UCMSCs的旁分泌作用促进皮片更快扩展融合,更利用UCMSCs的多向分化和炎症控制作用减轻瘢痕,从而解决战时成批大面积烧伤伤员救治困难的问题。  

Objectives of Study:

This study combines the umbilical cord mesenchymal stem cells (UCMSCs) with MEEK micrografting, the two advanced technologies that treat burn wounds, to form complementary advantages. That is, using MEEK micrografting for maximum skin source savings and using the paracrine role of UCMSCs to promote skin faster expansion, furthermore, the multidirectional differentiation and inflammatory control of UCMSCs can relieve scarring, thus to solve the difficult problem of treating large area burn patients in wartime.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

受试者选择对象为在我院烧伤外科手术病人。
受试者入选标准:(试验前,受试者必需满足项下所有要求,方可入组)
1)年龄18-60岁,男女不限;
2)烧伤总面积>30%TBSA;
3)病人同意参加本试验,并签署知情同意书;
4)AST、ALT、BUN、Cr不超过正常值一倍者;
5)非甲肝、乙肝、艾滋病、结核等传染性疾病处于活动期者;
6)受试者烧伤部位在前后躯干或肢体非手足部位。

Inclusion criteria

Subject inclusion criteria: (Subjects must meet all the requirements below before enrolled.)
1) Aged 18-60 years, male or female;
2) Total burn area > 30%TBSA;
3) The patient agrees to participate in this trial and signs the informed consent;
4) Blood level of AST, ALT, BUN, and Cr no more than twice the normal value;
5) Except the one infected with Hepatitis A, Hepatitis B, AIDS, tuberculosis or other infectious diseases in the active stage;
6) The burn sites of the subject include front and rear torso or limbs other than hands and feet.

排除标准:

受试者排除标准:(试验前,受试者满足项下任意一项要求,不可入组)
1)创面严重感染;
2)创周有皮肤疾病;
3)糖尿病患者;
4)装有心脏起搏器患者;
5)研究者认为不宜参加本临床试验的疾病患者。

Exclusion criteria:

Subject exclusion criteria: (Subjects meeting any of the requirements below shall not be enrolled.)
1) Severe wound infection;
2) Skin disease around the wound;
3) Diabetics;
4) Patients with cardiac pacemaker;
5) The researchers consider it inappropriate for patients with the disease to participate in this clinical trial.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

干预措施:

Interventions:

组别:

UCMSCs外用组

样本量:

8

Group:

External UCMSCs Group

Sample size:

干预措施:

UCMSCs以透明质酸凝胶为载体外用

干预措施代码:

Intervention:

External use of UCMSCs

Intervention code:

组别:

UCMSCs皮下注射组

样本量:

8

Group:

Hypodermic UCMSCs Group

Sample size:

干预措施:

UCMSCs以生理盐水为载体皮下注射

干预措施代码:

Intervention:

Hypodermic injection of UCMSCs

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

驻马店 

Country:

China 

Province:

Henan 

City:

Zhumadian 

单位(医院):

解放军第九九〇医院 

单位级别:

三甲 

Institution
hospital:

The 990th Hospital of PLA

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

愈合时间

指标类型:

主要指标

Outcome:

Healing time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

Pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瘢痕评分

指标类型:

主要指标

Outcome:

Scar score

Type:

Primary indicator

测量时间点:

测量方法:

温哥华瘢痕量表

Measure time point of outcome:

Measure method:

指标中文名:

瘢痕组织免疫组化

指标类型:

主要指标

Outcome:

Immunohistochemistry of scar tissue

Type:

Primary indicator

测量时间点:

测量方法:

HE, PCNA, Ki67, Masson, CD31

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

瘢痕组织块

组织:

皮肤组织

Sample Name:

Scar tissue mass

Tissue:

Skin tissue

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究负责人按随机数字表来决定实验组和对照组的位置,例如:逢奇数实验组在邻上位,逢偶数实验组在邻下位。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the random number table, the position of the experimental group and the control group are determined by the research leader. For example, every odd number matches the upper position and every even matches the lower.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023-06-01以后公开原始数据,论文附件或课题负责人邮件索取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be released after Jun 1st, 2023. The attachment of the paper or the email of the project leader will be available.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-12-16 05:33:42